Todays Report: Today, 36,941 Shares of Corcept Therapeutics Inc. (CORT) Stock are sold by Patrick G. Enright

Today, 36,941 Shares of Corcept Therapeutics Inc. (CORT) Stock are sold by Patrick G. Enright

Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 36,941 shares of the firm’s stock in a transaction dated Friday, November 25th. The stock was sold at an average price of $9.34, for a total transaction of $345,028.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.18 on Friday. The stock’s 50 day moving average is $7.78 and its 200 day moving average is $6.22. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 235.38 and a beta of 1.64. Corcept Therapeutics Inc. has a 12-month low of $3.22 and a 12-month high of $10.00.

Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in Corcept Therapeutics during the second quarter worth $100,000. Gotham Asset Management LLC increased its stake in Corcept Therapeutics by 39.2% in the third quarter. Gotham Asset Management LLC now owns 20,908 shares of the company’s stock worth $136,000 after buying an additional 5,884 shares during the period. Campbell & CO Investment Adviser LLC increased its stake in Corcept Therapeutics by 35.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 21,446 shares of the company’s stock worth $139,000 after buying an additional 5,652 shares during the period. Prudential Financial Inc. acquired a new stake in Corcept Therapeutics during the third quarter worth $141,000. Finally, BlackRock Group LTD increased its stake in Corcept Therapeutics by 5.1% in the third quarter. BlackRock Group LTD now owns 22,573 shares of the company’s stock worth $147,000 after buying an additional 1,089 shares during the period. Hedge funds and other institutional investors own 41.24% of the company’s stock.

Several analysts have commented on CORT shares. FBR & Co restated a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Zacks Investment Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Finally, Piper Jaffray Cos. set a $12.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 19th.

Corcept Therapeutics Company Profile

Related posts

Leave a Comment